Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06249438
What this trial is testing

C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Who this might be right for
Systemic Lupus Erythematosus (SLE)Immune-mediated Necrotizing Myopathy (IMNM)Neuromyelitis Optica Spectrum Disorders (NMOSD)+3 more
RenJi Hospital 30
Very early researchUnknownNCT04236011
What this trial is testing

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 15
Testing effectiveness (Phase 2)Study completedNCT03430011
What this trial is testing

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene 165
Early research (Phase 1)Active Not RecruitingNCT05835687
What this trial is testing

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Who this might be right for
Central Nervous System NeoplasmsAtypical Teratoid/Rhabdoid TumorDiffuse Midline Glioma, H3 K27M-Mutant+4 more
St. Jude Children's Research Hospital 29
Early research (Phase 1)Study completedNCT02893189
What this trial is testing

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation

Who this might be right for
CD19+ Malignancies: Relapse Post-allogeneic Transplant
University College, London 17
Testing effectiveness (Phase 2)UnknownNCT04206943
What this trial is testing

Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL

Who this might be right for
Acute Lymphoblastic LeukemiaNon Hodgkin Lymphoma
Acibadem University 24
Early research (Phase 1)Temporarily pausedNCT06071624
What this trial is testing

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

Who this might be right for
Chronic Myelomonocytic Leukemia
Huda Salman 30
Very early researchUnknownNCT05070156
What this trial is testing

B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular Carcinoma
Tongji University 3
Testing effectiveness (Phase 2)Looking for participantsNCT05338931
What this trial is testing

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Who this might be right for
B-cell Non Hodgkin Lymphoma
AbClon 82
Early research (Phase 1)Ended earlyNCT05623488
What this trial is testing

CAR T Cells in Mesothelin-Expressing Breast Cancer

Who this might be right for
Breast Cancer
University of Pennsylvania 2
Early research (Phase 1)UnknownNCT04121273
What this trial is testing

GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 20
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Early research (Phase 1)Looking for participantsNCT04099797
What this trial is testing

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

Who this might be right for
Diffuse Intrinsic Pontine GliomaHigh Grade GliomaEmbryonal Tumor+1 more
Baylor College of Medicine 56
Testing effectiveness (Phase 2)Study completedNCT03568461
What this trial is testing

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Who this might be right for
Follicular Lymphoma
Novartis Pharmaceuticals 98
Testing effectiveness (Phase 2)Looking for participantsNCT06733935
What this trial is testing

NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Who this might be right for
Systemic SclerosisIdiopathic Inflammatory MyopathiesAntineutrophil Cytoplasmic Antibody-Associated Vasculitis+1 more
Nkarta, Inc. 240
Testing effectiveness (Phase 2)Looking for participantsNCT07641023
What this trial is testing

Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

Who this might be right for
Non-Small Cell Lung CancerAdvanced/Metastatic
Beijing Biotech 60
Testing effectiveness (Phase 2)Ended earlyNCT05938725
What this trial is testing

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Who this might be right for
Lupus NephritisLupus Nephritis - World Health Organization (WHO) Class IIILupus Nephritis - WHO Class IV
Kyverna Therapeutics 6
Early research (Phase 1)Active Not RecruitingNCT02663297
What this trial is testing

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Who this might be right for
Hodgkin DiseaseLymphomaLymphoma, Non-Hodgkin+6 more
UNC Lineberger Comprehensive Cancer Center 18
Early research (Phase 1)Study completedNCT01593696
What this trial is testing

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

Who this might be right for
ALLB Cell LymphomaLeukemia+2 more
National Cancer Institute (NCI) 53
Not applicableUnknownNCT06041815
What this trial is testing

Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies

Who this might be right for
Hematological MalignanciesChimeric Antigen Receptor T-cell Therapy
The First Affiliated Hospital of Soochow University 100
Next Page